May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Effect of 7-Methylxanthine on Eye Growth in Myopic Children - 36-Months Follow-Up
Author Affiliations & Notes
  • K. Trier
    Trier Research Laboratories, Hellerup, Denmark
  • S. M. Ribel-Madsen
    Trier Research Laboratories, Hellerup, Denmark
  • Footnotes
    Commercial Relationships  K. Trier, Øjenlæge Klaus Trier ApS, F; Øjenlæge Klaus Trier ApS, E; US patent 6,710,051, P; S.M. Ribel-Madsen, None.
  • Footnotes
    Support  "Jørgen Bagenkop Nielsens Myopi-Fond", "Generalkonsul Einar Høyvalds Fond", "Øjenlæge Klaus Trier ApS"
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2609. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Trier, S. M. Ribel-Madsen; Effect of 7-Methylxanthine on Eye Growth in Myopic Children - 36-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2609.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

In sclera from myopic eyes, collagen content is reduced. The adenosine antagonist 7-methylxanthine (7-mx), a theobromine metabolite, increases collagen in rabbit sclera and may therefore hypothetically reduce eye elongation in childhood myopia. In a 12-months clinical trial, 68 myopic children (mean age 11.3 years) with a minimum base-line axial growth rate of 0.075 mm per six months received either placebo tablets or 7-mx, 400 mg per day. Participants from both groups subsequently received 7-mx for another 12 months. At 24 months, a significantly lower axial growth was found among children treated with 7-mx for 24 months compared with those only treated for 12 months. Treatment with 7-mx was then stopped in both groups.


Axial length was measured with Zeiss IOL-Master at -6, 0, 12, 24, and 36 months.


33 children completed 36-months follow-up (interim data). In the group treated with 7-mx 0-24 months (n=16), axial growth rate in the first as well as the second year of treatment was significantly lower compared with the precedent period (p<0.0001 and p=0.004). In the group treated with 7-mx 12-24 months (n=17), a significant drop in axial growth rate was only seen during treatment with 7-mx (p=0.01). Axial growth rate 24-36 months was in neither group significantly different from the precedent period (p=0.090 and p=0.363).


During treatmentwith 7-mx, axial growth continuously decreases, but when treatment is stopped, the effect disappears. These results confirm that 7-mx reduces eye elongation in myopia. The treatment is safe and without side-effects and may be continued until 18-20 years of age when age-related cross-linking of collagen prevents further elongation of the eye.  

Clinical Trial: NCT00263471

Keywords: myopia • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.